...
首页> 外文期刊>Blood: The Journal of the American Society of Hematology >T-cell independent, B-cell receptor-mediated induction of telomerase activity differs among IGHV mutation-based subgroups of chronic lymphocytic leukemia patients
【24h】

T-cell independent, B-cell receptor-mediated induction of telomerase activity differs among IGHV mutation-based subgroups of chronic lymphocytic leukemia patients

机译:慢性淋巴细胞性白血病患者基于IGHV突变的亚组中,T细胞独立,B细胞受体介导的端粒酶活性诱导不同

获取原文
获取原文并翻译 | 示例
           

摘要

Although B-cell chronic lymphocytic leukemia (B-CLL) clones with unmutated IGHV genes (U-CLL) exhibit greater telomerase activity than those with mutated IGHV genes (M-CLL), the extent to which B-cell receptor (BCR) triggering contributes to telomerase up-regulation is not known. Therefore, we studied the effect of BCR stimulation on modulating telomerase activity. The multivalent BCR ligand, dextran conjugated anti-μ mAb HB57 (HB57-dex), increased telomerase activity and promoted cell survival and proliferation preferentially in U-CLL cases, whereas the PI3K/Akt inhibitor LY294002 blocked HB57-dex induced telomerase activation. Although both U-CLL and M-CLL clones exhibited similar membrane proximal signaling responses to HB57-dex, telomerase activity and cell proliferation, when inducible in M-CLL, differed. B-CLL cells stimulated using bivalent F(ab′) 2-goat anti-μ antibody (goat anti-μ) exhibited higher membrane proximal response in U-CLL than M-CLL cells, whereas telomerase activity, cell survival, and proliferation were induced to lower levels than those induced by HB57-dex. In normal B lymphocytes, HB57-dex induced less protein phosphorylation but more cell proliferation and survival than goat anti-μ. Although both anti-BCR stimuli induced comparable telomerase activity, normal CD5 + B cells preferentially exhibited higher hTERT positivity than their CD5 -counterparts. These findings provide an understanding of how BCR-mediated signals impact telomerase modulation in IGHV mutation-based subgroups of B-CLL and normal B cells.
机译:尽管具有未突变IGHV基因(U-CLL)的B细胞慢性淋巴细胞性白血病(B-CLL)克隆比具有IGHV突变基因(M-CLL)的克隆具有更高的端粒酶活性,但是B细胞受体(BCR)触发的程度导致端粒酶上调的原因尚不清楚。因此,我们研究了BCR刺激对调节端粒酶活性的影响。在U-CLL病例中,多价BCR配体右旋糖酐偶联的抗μmAb HB57(HB57-dex)可以增加端粒酶活性并优先促进细胞存活和增殖,而PI3K / Akt抑制剂LY294002可以阻断HB57-dex诱导的端粒酶激活。尽管U-CLL和M-CLL克隆都表现出相似的对HB57-dex的膜近端信号传导响应,但在M-CLL中诱导时,端粒酶活性和细胞增殖却有所不同。使用二价F(ab')2山羊抗μ抗体(山羊抗μ)刺激的B​​-CLL细胞在U-CLL中表现出比M-CLL细胞更高的膜近端反应,而端粒酶活性,细胞存活和增殖诱导水平低于HB57-dex诱导水平。在正常的B淋巴细胞中,与山羊抗μ相比,HB57-dex诱导的蛋白磷酸化较少,但细胞增殖和存活率更高。尽管两种抗BCR刺激都能诱导可比的端粒酶活性,但正常的CD5 + B细胞优先表现出比其CD5-对应物更高的hTERT阳性。这些发现提供了对BCR介导的信号如何影响基于IGHV突变的B-CLL和正常B细胞​​亚组中端粒酶调节的理解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号